4.73
Schlusskurs vom Vortag:
$4.51
Offen:
$4.6
24-Stunden-Volumen:
394.86K
Relative Volume:
0.38
Marktkapitalisierung:
$233.82M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-2.7988
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-4.02%
1M Leistung:
-41.05%
6M Leistung:
-16.35%
1J Leistung:
-14.24%
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CADL
Candel Therapeutics Inc
|
4.73 | 233.82M | 124.00K | -49.99M | -31.03M | -1.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.37 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
582.37 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.96 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.84 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.00 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-20 | Eingeleitet | Citigroup | Buy |
2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
2025-02-07 | Eingeleitet | BofA Securities | Buy |
2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
2021-08-23 | Eingeleitet | Jefferies | Buy |
2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel reports positive phase 1b glioma trial results By Investing.com - Investing.com UK
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Paul Tak Sells 26,172 Shares of Candel Thera - GuruFocus
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel therapeutics CEO sells $229,624 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan
Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com
Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors
Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times
Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire
Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Nichols William Garrett | Chief Medical Officer |
Mar 18 '25 |
Sale |
8.76 |
45,316 |
396,995 |
52,493 |
Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Option Exercise |
1.55 |
18,000 |
27,900 |
128,673 |
Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Sale |
8.76 |
32,146 |
281,673 |
96,527 |
Tak Paul Peter | Chief Executive Officer |
Mar 18 '25 |
Sale |
8.77 |
25,772 |
226,023 |
226,140 |
Tak Paul Peter | Chief Executive Officer |
Mar 19 '25 |
Sale |
9.00 |
400 |
3,601 |
225,740 |
Tyagarajan Seshu | Chief Technology Officer |
Mar 17 '25 |
Sale |
8.82 |
31,278 |
275,947 |
85,512 |
Schoch Charles | See Remarks |
Mar 17 '25 |
Sale |
8.83 |
5,000 |
44,169 |
38,038 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):